The Life Sciences and Special Purpose Acquisition Companies (SPACs) teams advised Immatics N.V. (NASDAQ: IMTX) on its business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA) and new listing on NASDAQ. Immatics began trading on July 2 at $15.75 per share, giving Immatics an implied market valuation of nearly $1 billion. The business combination included new investments from leading institutional investors for an additional $104 million in private placement in public equity (“PIPE”) and $149 million from Arya’s trust account, resulting in approximately $253 million in transaction proceeds for Immatics.
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies. Arya is a special purpose acquisition company (SPAC), sponsored by Perceptive Advisors.
The Goodwin team led by Jocelyn Arel, Mitch Bloom and Michael Patrone, and included Edwin O’Connor, Elena Hera, Humza Bokhari, Rob Intile, Sarah Bock, James Devendorf, Theresa Kavanaugh, Megan Gustafson, Daniel Karelitz, Alex Apostolopoulos, Nicole Spiteri, Roger Cohen, Steven Tjoe, Jennifer Fay, Deborah Birnbach, Caroline Bullerjahn, Brian Mukherjee, Alicia Rubio-Spring, Paul Jin, and Kara Kuritz.
For more details, read the press release and articles in Law360, PE Hub, and Endpoints.